Ken Griffin Oncternal Therapeutics, Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.28 - $0.64 $15,198 - $34,738
54,279 New
54,279 $29,000
Q1 2023

May 15, 2023
SELL
$0.63 - $1.3 $1,006 - $2,077
-1,598 Reduced 29.0%
3,913 $3,000
Q4 2022

Feb 14, 2023
BUY
$0.86 - $22.2 $4,739 - $122,344
5,511 New
5,511 $5,000

Others Institutions Holding ONCT

# of Institutions
3
Shares Held
362K
Call Options Held
0
Put Options Held
0
View Full List

About Oncternal Therapeutics, Inc.

ONCT Quotes by TradingView
  • Ticker ONCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,517,200
  • Market Cap $29.4M
  • Description
  • Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...
More about ONCT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email